Spyre Therapeutics, Inc SYRE 深 沪
等待开盘 08-19 09:30:00 美东时间
107.82
+3.220
+3.08%
华盛通- 最 高108.62
- 今 开102.46
- 成交量 94.96万股
- 最 低 101.4393
- 昨 收 104.60
- 总市值 95.07亿
- 52周最高 108.62
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 14.505
- 委 比 -23.08%
- 总股本 8817.38万
- 历史最高 318.75
- 量 比 1.24
- 振 幅 6.86%
- 历史最低 2.66
- 每 手 1
- 风险率 28.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keefe, Bruyette & Woods raised the price target for Marketaxess Holdings Inc (NASDAQ:MKTX) from $150 to $167. ...
08-11 19:59
美股夜盘 | AXT Inc上升5.06%，Barrick Mining上升3.37%
Sphere Entertainment跌3.12%；Spyre Therapeutics, Inc跌3.00%；SiTime Corporation跌2.91%
08-10 08:05
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.
08-05 21:27
Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.73) by 50.68 percent. This is a 26.53 percent increase over losses of $(0.49) per share from the same period last year.
08-05 04:52
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Wolfe Research analyst Andy Chen downgrades Spyre Therapeutics (NASDAQ:SYRE) from Outperform to Peer Perform.
07-29 00:17
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120
Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $84 to $120.
07-13 18:50
